Cancer Research, Statistics, and Treatment (Jan 2021)

Totally implantable venous access devices in cancer chemotherapy: A retrospective analysis of 8421 catheter days in a tertiary cancer center

  • Jashma Chandveettil,
  • Abhay K Kattepur,
  • Nizamudheen Mangalasseri Pareekutty,
  • John J Alapatt,
  • Appumathi Rogarajan Mathiyazhakan,
  • Ratheesan Kumbakara,
  • Vivek M Ananthakrishna Murthy,
  • Satheesan Balasubramanian

DOI
https://doi.org/10.4103/crst.crst_119_21
Journal volume & issue
Vol. 4, no. 3
pp. 449 – 455

Abstract

Read online

Background: The management of several malignancies requires prolonged venous access and repeated injections. While totally implantable venous access devices (TIVADs) can help circumvent many difficulties related to repeated venous cannulation, these devices are associated with their own share of complications. Objectives: In this study, we report our experience with TIVADs, the complications associated with them and their salvage rate. Materials and Methods: This retrospective study of adult patients who underwent TIVAD insertion for cancer cytotoxic chemotherapy between January 2016 and December 2020 was conducted at Malabar Cancer Center, a tertiary cancer center in Kerala, India. The majority of the catheters were inserted using the modified Seldinger's technique into the right internal jugular vein under ultrasonographic guidance. Local anesthesia was used for pain relief during the procedure in the majority of patients. The number of catheter days, rate of complications associated with the use of TIVADs and their nature, and the salvage measures undertaken along with their outcomes were recorded. Results: A total of 37 catheters were inserted in 34 patients during the study period. The total number of catheter days was 8421, and the average number of catheter days was 227.6 days per patient. Postoperative complications developed after the insertion of 7 catheters (18.9%), the most common complication being infection. Three catheters (42.9%) could be salvaged after complications. Twenty-eight (87.5%) catheters were available for use till the end of the planned chemotherapy. Five patients are currently receiving chemotherapy and their catheters are in situ. Conclusion: TIVADs are convenient for long-term venous access in patients with cancer and provide safe and continuous venous access till the completion of chemotherapy.

Keywords